Vertex Pharmaceuticals Inc. closed 10.29% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. | The FDA has ...

Looking ahead, Vertex Pharmaceuticals remains optimistic about its growth prospects, driven by ongoing product developments and potential new launches. The company’s strategic initiatives and ...

KING OF PRUSSIA, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new innovations ...

CRISPR treatment for sickle cell disease carries a high risk of infertility. Vertex wants to preserve patient fertility, but a federal rule poses problems.

Take a behind-the-scenes look at the rover that will soon begin exploring the mystery of the Moon's strange magnetic anomalies.

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

Vertex and CRISPR Therapeutics just won a regulatory nod for exa-cel, to be sold as Casgevy, for the treatment of sickle cell disease. With this approval, Vertex proved something big to investors ...